This strain, which has generated a significant amount of global media attention, is called B.1.617.2.1 or AY.1 — Delta Plus for short, and is a version of the Delta variant first detected in India in February.
The Indian government said it has submitted the variant to the Global Data System, and sent samples for genomic testing.
About 200 cases have been spotted in 11 countries. Health experts are investigating whether Delta Plus may be more transmissible than other strains like the Alpha or Delta variants — but it’s too early to say for sure what its effects may be.
Here’s what we know so far, and what questions are still unanswered.
How is Delta Plus different from the Delta variant?
All variants carry clusters of mutations. Delta Plus has an extra mutation called K417N, which distinguishes it from the regular Delta variant. This mutation affects the spike protein, the part of the virus that attaches to the cells it infects.
The K417N mutation isn’t entirely new — it has “arisen independently in several viral lineages,” said Francois Balloux, director of the University College London (UCL) Genetics Institute.
“The mutation may contribute to immune escape, though its impact on transmissibility is not clear-cut,” he added.
All viruses mutate constantly. Some of those changes make viruses better at infecting cells, or better at replicating, while others have little effect or are even harmful to the virus.
To date, there have been about 160 strains of the coronavirus sequenced globally, said Balloux.
There are also “other Delta plus variants with other mutations,” said the Indian government on Wednesday, adding that AY.1 was just the most well known.
Maria Van Kerkhove, the World Health Organization’s technical lead on Covid-19, added that the team was “looking at these specific mutations and what these mean in terms of transmission, in terms of severity, and really importantly what these means in terms of our medical countermeasures.”
Is it more infectious or deadly?
According to the Indian government’s Covid-19 genome sequencing body, the Delta Plus variant exhibits several worrying traits such as increased transmissibility, stronger binding to receptors of lung cells, and a potential reduction in antibody response.
Most of the coronavirus vaccines are designed to train the body to recognize the spike protein, or parts of it — the place where Delta Plus’ extra mutation is.
However, there isn’t enough evidence to determine anything conclusively yet and other experts have expressed caution. On Wednesday, the Indian government said the mutation’s role in “immune escape, disease severity or increased transmissibility etc. is under continued surveillance.”
For now, experts are largely cautioning the public and governments to remain watchful but calm.
Besides the Beta variant, none of the other strains carrying the K417N mutation “have been particularly successful so far,” said Balloux. “It has been found in several countries but has remained at extremely low frequency … There is no evidence the strain is currently expanding in any country.”
Van Kerkhove from WHO said the organization was tracking Delta Plus to determine its transmissibility and severity.
Where has it been found?
So far, Delta Plus has been reported in 11 countries — but the number of cases per country only reflects samples that have been sequenced, and more data is needed to determine the actual rate of spread.
The UK is next, with 41 cases as of June 16. Enhanced contact tracing, testing, and isolation has been deployed in areas where Delta Plus has been reported, Downing Street confirmed on Thursday.
The first few cases sequenced in the UK were contacts of individuals who had traveled from or transited through Nepal and Turkey, according to Public Health England.
India follows at 40 cases, the government said on Wednesday. The cases are spread across three states — Maharashtra, Kerala and Madhya Pradesh. On Tuesday, the Indian health ministry designated it a “variant of concern,” and placed all three states on alert.
The government said the number of cases was still low — but urged states with cases to “enhance their public health response” by stepping up testing, tracing, and priority vaccination.
The rest of the cases are spread out between Canada, India, Japan, Nepal, Poland, Portugal, Russia, Switzerland, and Turkey.